GlassScriptPhysician profile
Katelyn Pike
NPI 1396410866
$3,707.76
in general payments reported to CMS, 2019-2025
20 companies · $922 in 2025
The $922 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $417 · 2023: $738 · 2024: $1,631 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,237 · Education: $53.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,237.10 |
| Education | $53.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $520.84 | 2023-2025 | Tarpeyo |
| Amgen INC. | $512.65 | 2022-2025 | Krystexxa, Parsabiv, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $315.19 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $304.16 | 2022-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $286.98 | 2022-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $281.49 | 2022-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $262.51 | 2022-2025 | Jynarque |
| Akebia Therapeutics INC | $237.13 | 2024-2025 | Auryxia, Vafseo |
| Novo Nordisk INC | $193.91 | 2024-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $167.89 | 2023-2025 | |
| Lilly USA, LLC | $99.92 | 2023-2024 | Jardiance |
| Axonics, INC. | $94.57 | 2024 | Axonics |
| Travere Therapeutics, INC. | $94.22 | 2023-2025 | |
| Ardelyx, INC. | $91.59 | 2024-2025 | Ibsrela |
| Horizon Therapeutics Plc | $54.92 | 2023 | Krystexxa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $53.79 | 2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.02 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $42.76 | 2022-2023 | Ultomiris |
| Vifor Pharma, INC. | $30.81 | 2024 | Veltassa |
| Shield Therapeutics INC | $13.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Pike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.